Raul A Torres
Nursing at 17 Ave, Denver, CO
License number
Colorado 775662
Issued Date
Oct 26, 2016
Renew Date
Oct 26, 2016
Expiration Date
Jan 31, 2019
Type
Certified Nurse Aide
Address
Address
4300 W 17Th Ave, Denver, CO 80204
Professional information
Professor Of Immunology At University Of Colorado School Of Medicine And National Jewish Health
Position:
Professor of Immunology and Immunology Graduate Program Director at UCD and NJH, Co-Founder, Chief Scientific Officer at Lenimen
Location:
Greater Denver Area
Industry:
Research
Work:
UCD and NJH
- University of Colorado School of Medicine and National Jewish Health since Mar 2001
-
Professor of Immunology and Immunology Graduate Program Director
Lenimen
since Apr 2012
-
Co-Founder, Chief Scientific Officer
Basel Institute for Immunology
- Basel, Switzerland Jun 1996 - Mar 2001
-
Scientific Member
Institute for Genetics, University of Cologne
- Cologne, Germany Jan 1992 - Jun 1996
-
Postdoctoral fellow
Education:
University of Washington School of Medicine
Doctor of Philosophy (Ph.D.), Immunology
Doctor of Philosophy (Ph.D.), Immunology
Pulmonary Disease Treatment And Diagnosis Based On Arhgef1
US Patent:
2013028, Oct 31, 2013
Filed:
Jan 13, 2012
Appl. No.:
13/979410
Inventors:
Raul M. Torres - Denver CO, US
John Hartney - Arvada CO, US
Roberta Pelanda - Denver CO, US
John Hartney - Arvada CO, US
Roberta Pelanda - Denver CO, US
Assignee:
The Regents of the University of Colorado, a body corporate - Denver CO
International Classification:
A61K 31/192, C12Q 1/68, G01N 33/577
US Classification:
514570, 435 612, 436501, 435 611
Abstract:
Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.